THC Farmaceuticals Inc. Stock Analysis CBDG
THC Farmaceuticals, Inc. engages in the research and development of cannabis pharmaceutical products. The company is headquartered in Scottsdale, Arizona and currently employs 2 full-time employees. The company went IPO on 2012-08-22. The firm specializes in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology and other medical disciplines. The company offers the combination of its proprietary developments with its clinicians and scientists to unlock the therapeutic properties of cannabis and its bioactive compounds. The firm owns clinical research center and cannabidiol (CBD) manufacturing facility in California. Its business plan includes conducting cannabinoids research and development in collaboration with cannabis research centers worldwide with the goal of developing novel and advanced therapeutic methods for the treatment of common medical conditions with cannabis-based therapies and to conduct pre-clinical investigations and randomized, placebo-controlled trials of CBD-based compounds and develop condition-specific medications. The company offers a network of micro vending kiosk systems.
Read More THC Farmaceuticals Inc (CBDG) Chart
Key Statistics of THC Farmaceuticals Inc (CBDG)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.02Volume
5229.00P/E Ratio (TTM)
0.7652 Week Range
Market Cap
326.37KAvg. Volume
3490.00Dividend Yield
-Financial Metrics & Statements of THC Farmaceuticals Inc (CBDG)
FAQ's for THC Farmaceuticals Inc (CBDG)
- According to Musaffa’s Shariah screening methodology, THC Farmaceuticals Inc (CBDG) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.